CytomX Therapeutics
CTMX
122 hedge funds and large institutions have $698M invested in CytomX Therapeutics in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 34 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
0.9% more ownership
Funds ownership: 83.16% → 84.06% (+0.9%)
6% less capital invested
Capital invested by funds: $739M → $698M (-$41.2M)
14% less funds holding
Funds holding: 142 → 122 (-20)
55% less call options, than puts
Call options by funds: $724K | Put options by funds: $1.62M
59% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 34
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$17.6M |
| 5 |
PA
Perceptive Advisors
New York
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$8.46M |
| 2 |
TCP
Tourbillon Capital Partners
New York
|
-$6.92M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$6M |
| 4 |
Man Group
London,
United Kingdom
|
-$4.23M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$2.31M |
CTMX Hedge Fund Activity: Q3 2018 in Review
122 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2018, worth a combined $698M — down 5.6% from $739M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of CTMX and 14 opened new positions — a net loss of 20 holders — while 31 trimmed existing stakes and 55 added.
The largest buyer was Point72 Asset Management, adding an estimated $26.6M. The largest seller was Invesco, cutting an estimated $8.46M.
- 122 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2018, down from 142 in Q2 2018.
- Funds reported $698M of CytomX Therapeutics stock for Q3 2018, down 5.6% quarter-over-quarter.
- 14 funds opened new CytomX Therapeutics positions in Q3 2018 and 34 closed out, a net change of -20 holders.
- The largest CytomX Therapeutics buyer in Q3 2018 was Point72 Asset Management, an estimated $26.6M added.
- The largest CytomX Therapeutics seller in Q3 2018 was Invesco, an estimated $8.46M sold.
Based on aggregated 13F filings for Q3 2018.